3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
18
Prostatic Neoplasms
10
Liver Neoplasms
7
Carcinoma, Hepatocellular
6
Neoplasm Metastasis
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Unresectable Pancreatic Cancer
2
Stomach Neoplasms
2
Neoplasms
2
Lymphatic Metastasis
2
Locally Advanced Pancreatic Cancer
2
Kidney Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor Including Thyroid, Bone, Liver, Pancreas
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Adenocarcinoma Resectable
1
Pancreatic Adenocarcinoma Locally Advanced
1
Melanoma
1
Liver, Cancer of, Non-Resectable
1
Liver Metastasis Colon Cancer
1
Interventions
Cisplatin
109
Radiotherapy
100
Fluorouracil
90
Paclitaxel
75
Oxaliplatin
63
Docetaxel
56
Carboplatin
55
Irinotecan
41
Esophagectomy
41
Leucovorin
40
Capecitabine
39
Surgical Procedures, Operative
36
Radiation
36
Drug Therapy
31
Neoadjuvant Therapy
25
Chemoradiotherapy
18
Cetuximab
18
S 1 (combination)
17
pembrolizumab
16
camrelizumab
16
Nivolumab
15
Magnetic Resonance Spectroscopy
15
Bevacizumab
15
Blood Specimen Collection
14
Surveys and Questionnaires
12
Radiotherapy, Intensity-Modulated
12
Immunotherapy
11
Epirubicin
11
Biopsy
11
Trastuzumab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Esophageal Neoplasms
×
Electroporation
×
Clear all
NCT02430701
2021-09-05
IRE
Fuda Cancer Hospital, Guangzhou
Phase NA
Completed
30 enrolled